Merck's Keytruda wins FDA approval as combination therapy for kidney cancer
The U.S. Food and Drug Administration has approved Merck& Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Health | Kidney Cancer | Merck | Urology & Nephrology